title: Successful Eradication Therapy for Helicobacter pylori-positive Atrophic Gastritis at the Sixth Attempt: A Case Report.
abstract: A 74-year-old woman undergoing outpatient follow-up for reflux esophagitis and atrophic gastritis tested positive for Helicobacter pylori and underwent primary eradication therapy with lansoprazole (LPZ) 30 mg, amoxicillin (AMPC) 750 mg, and clarithromycin (CAM) 200 mg twice daily for 1 week in August 2012. A urea breath test (UBT) after this treatment revealed that eradication had failed. Secondary eradication therapy was carried out with esomeprazole (EPZ) 20 mg, AMPC 750 mg, and metronidazole (MNZ) 250 mg twice daily for 1 week, but this also failed. The third attempt at eradication consisted of EPZ 20 mg, AMPC 750 mg, and sitafloxacin (STFX) 100 mg twice daily for 1 week, but this also ended in failure. A fourth attempt using rabeprazole (RPZ) 20 mg (4 times daily) with MNZ 250 mg and STFX 100 mg twice daily for 2 weeks also failed, as did a fifth attempt in April 2015 using vonoprazan (VPZ) 20 mg, AMPC 750 mg, and MNZ 250 mg twice daily for 1 week. Eradication was finally successful after the sixth attempt, in which the patient was treated with vonoprazan 20 mg, MNZ 250 mg, and STFX 100 mg twice daily for 2 weeks.
authors.affiliation: Department of Gastroenterology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. deguchi@is.icc.u-tokai.ac.jp.
authors.forename: Ryuzo
authors.initials: R
authors.lastname: Deguchi
authors.forename: Koichi
authors.initials: K
authors.lastname: Shiraishi
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Arase
authors.forename: Makiko
authors.initials: M
authors.lastname: Dekiden
authors.forename: Hideo
authors.initials: H
authors.lastname: Shimada
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Miyakita
authors.forename: Takashi
authors.initials: T
authors.lastname: Ogimi
authors.forename: Kazunori
authors.initials: K
authors.lastname: Myojin
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Mine
mesh_terms: D000368:Aged; D004359:Drug Therapy, Combination; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage*; D005757:Gastritis, Atrophic / Q000188:drug therapy* / Q000382:microbiology*; D016481:Helicobacter Infections; D016480:Helicobacter pylori; D006801:Humans; D008795:Metronidazole / Q000008:administration & dosage*; D011758:Pyrroles / Q000008:administration & dosage*; D013449:Sulfonamides / Q000008:administration & dosage*; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: C552956:1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine; D024841:Fluoroquinolones; D011758:Pyrroles; D013449:Sulfonamides; D008795:Metronidazole; C076246:sitafloxacin